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Carboxypeptidase inhibition by NvCI suppresses airway 
hyperreactivity in a mouse asthma model
To the Editor,
Mast cells are implicated in asthma, and an emerging body of 
evidence suggests that proteases released by mast cells are crucial 
players in asthma pathogenesis.1 The mast cell–restricted proteases, 
that is tryptase, chymase and carboxypeptidase A3 (CPA), are stored 
in large amounts as active enzymes in secretory granules in mast 
cells. Experimental studies in mouse models suggest that trypt-
ase can contribute to airway hyperreactivity (AHR), a hallmark of 
asthma, whereas chymase can attenuate several features of asthma 
including AHR and IL-33 accumulation in lungs.2,3 In contrast, there 
is very limited information on the role of CPA3 in asthma pathogen-
esis. However, findings from clinical studies suggest a link between 
Th2-high asthma and expression of CPA3 in the lungs.4,5 CPA3 is a 
proteolytic enzyme with CPA-like activity, which means that it can 
remove aromatic and aliphatic residues at the C-terminal end of tar-
get proteins and peptides.6 Considering that lung mast cells release 
large amounts of proteolytically active CPA3 upon degranulation, 
we hypothesized that CPA activity in lung tissue could have a pro-
found effect on the asthma response.
Here, we investigated the contribution of CPA activity to fea-
tures of asthma using the Nerita versicolor carboxypeptidase inhibi-
tor (NvCI) in a mouse model of allergic asthma. NvCI is the strongest 
natural CPA inhibitor described so far, with inhibitory constants in 
the picomolar range, and also displays remarkable bioavailability and 
resistance.7 NvCI is highly specific for the M14A carboxypeptidase 
subfamily, including CPA3. To confirm the inhibitory effect of NvCI 
on mast cell CPA3, we used a chromogenic CPA substrate (M-2245/
AAFP). We found that addition of NvCI completely inhibited CPA 
activity in supernatants of murine mast cells that were degranulated 
by IgE cross-linking or calcium ionophore (Figure 1A). Moreover, we 
detected weak CPA activity in human lung homogenates that was 
undetectable after adding NvCI (Figure 1B). These findings confirm 
that NvCI is a potent inhibitor of CPA activity derived from mast cells 
and located in lung tissue.
We then investigated the effect of CPA inhibition in a house dust 
mite (HDM)–induced asthma model. Female mice of the BALB/c 
strain were pretreated with intraperitoneal injections of NvCI fol-
lowed by intranasal instillations with HDM extract twice weekly 
for three weeks (Figure S1). Control groups of mice received HDM, 
buffer (PBS) or NvCI alone, at the same days. Resident mast cells in 
mouse lungs contain substantial amounts of CPA,1,8 and we found 
increased degranulation of these mast cells upon HDM exposure 
(Figure S2), hence indirectly confirming the release of CPA in this 
model. Moreover, we confirmed the absence of CPA-like activity 
in the HDM extract (data not shown) and found that NvCI treat-
ment of mice reduced the total CPA activity in lung homogenates 
(Figure 1C). We assessed AHR by measuring the change in lung re-
sistance and dynamic compliance in response to nebulized metha-
choline compared with baseline values (PBS controls). As expected, 
mice challenged with HDM exhibited increased lung resistance 
and decreased dynamic compliance compared with control mice, 
whereas mice injected with NvCI alone did not differ from controls 
(Figure 1D). Notably, there was no AHR in the group of NvCI-treated 
HDM-challenged mice, as demonstrated by normalization of airway 
resistance and dynamic compliance in these mice (Figure 1D). This 
strongly supports the notion that CPA activity contributes to the de-
velopment of AHR in the HDM-induced asthma model. To determine 
whether the NvCI-mediated attenuation of AHR was accompanied 
by a decrease in airway inflammation, we analysed HDM-induced 
accumulation of total cells, eosinophils, macrophages, lymphocytes 
and neutrophils in bronchoalveolar lavage (BAL). We found that 
NvCI treatment did not have any statistically significant effect on 
total or differential cell counts in BAL, although there was a trend 
for decreased numbers of eosinophils in NvCI-pretreated, HDM-
challenged mice (Figure 1E-I).
To determine the influence of NvCI on tissue inflammation and 
remodelling in the asthma model, lung sections were stained with 
periodic acid-Schiff (PAS) or haematoxylin and eosin and analysed 
for goblet cell accumulation, inflammatory cell infiltrates and thick-
ening of airway smooth muscle layer. The results showed that NvCI 
significantly decreased accumulation of goblet cells in airway epi-
thelium (Figure 2A, B), suggesting that CPA activity contributes to 
epithelial remodelling induced by HDM exposure. In agreement with 
the lack of effect on the inflammatory cells of the BAL fluid, NvCI 
did not influence the HDM-induced infiltration of inflammatory 
cells around airways or blood vessels (Figure 2C-E). Thickness of the 
smooth muscle layer in lung tissue did not differ between groups, 
and hence, no influence of NvCI was detected (Figure 2F).
We have previously shown that extracellular levels of IL-13 and 
IL-33 can be limited by proteolytic degradation exerted by mast 
cell serine proteases, including chymase.3,9 Notably, intra-epithe-
lial mast cells in asthma exhibit an aberrant protease profile (trypt-
ase+, CPA3+ and chymase−)4 and was recently shown to augment 
epithelial IL-33,10 suggesting an overall detrimental role of these 
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mast cells. To examine the effect of CPA inhibition on cytokine con-
centrations, we measured a panel of pro-inflammatory cytokines 
in lung tissue extracts by ELISA. Concentrations of IL-5, IL-33 and 
CXCL-1 were increased upon HDM challenge, but there was no sta-
tistical difference between NvCI-treated and non-treated groups of 
HDM-challenged mice (Figure 2G). Hence, we found no evidence 
for a regulatory role of CPA activity on levels of cytokines in this 
model.
To summarize, we demonstrated that NvCI can efficiently inhibit 
CPA activity derived from murine mast cells or human lungs. In the 
HDM-induced asthma model, pre-treatment with NvCI reduced the 
lung CPA activity and protected against AHR and reduced goblet cell 
F I G U R E  1   Carboxypeptidase inhibitor NvCI inhibits CPA-like activity and reduces AHR, but does not modify BAL leucocyte influx 
following HDM challenge. A, CPA-like activity in mast cell supernatants, B, in human lung and C, in mouse lung homogenates (udl, under 
detection level). D, Lung resistance (RL) and dynamic compliance (Cdyn; n = 6–9). HDM versus control (PBS): **p < 0.01, ***p < 0.001; HDM 
versus NvCI +HDM ††† p < 0.001; HDM versus NvCI ++p < 0.01 (two-way ANOVA). E-I, Total and differential counts of cells in BAL 
(n = 6–9). *p < 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA). Data were obtained from 4 independent experiments
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F I G U R E  2   HDM-induced tissue inflammation and remodelling in NvCI-treated mice. A, Periodic acid-Schiff's (PAS) staining (arrows) of 
lung sections. B, Number of PAS+ cells per µm airway epithelia (n = 6–9). C-E, Leucocyte infiltrates in the lung tissue (n = 6–9). F, Thickness of 
airway smooth muscle layer (n = 6–8). G, Cytokine concentrations in lung homogenates (n = 6–9). *p < 0.05, **p < 0.01, ***p < 0.001 (one-way 
ANOVA). Data were obtained from 4 independent experiments
Co
ntr
ol
HD
M
Nv
CI
Nv
CI
+ H
DM
0
10
20
30
40
IL
-6
(p
g/
m
l)
Co
ntr
ol
HD
M
Nv
CI
Nv
CI
+ H
DM
0
5
10
15
20
IL
-5
(p
g/
m
l)
*
Co
ntr
ol
HD
M
Nv
CI
Nv
CI
+ H
DM
0
20
40
60
80
100
C
XC
L1
(K
C
)(
pg
/m
l) *
Co
ntr
ol
HD
M
Nv
CI
Nv
CI
+ H
DM
0
100
200
300
400
Eo
ta
xi
n
(p
g/
m
l)
Control NvCI(A) HDM NvCI + HDM
Co
ntr
ol
HD
M
Nv
CI
Nv
CI
 + 
HD
M
0.00
0.05
0.10
0.15
0.20
0.25
***
***
*
SAP
+
mµ/sllec
Co
ntr
ol
HD
M
Nv
CI
Nv
CI
 + 
HD
M 
0
10
20
30
40
(µ
ssenkciht
MS
A
m
)
Co
ntr
ol
HD
M
Nv
CI
Nv
CI
 + 
HD
M
0.0
0.5
1.0
1.5
*
)l
m/gn(
33-LI
Co
ntr
ol
HD
M
Nv
CI
Nv
CI
 + 
HD
M
0
10
20
30
40
)l
m/gp(
31-LI
Co
ntr
ol
HD
M
Nv
CI
Nv
CI
+ H
DM
0
50
100
150
C
el
ls
pe
rf
ie
ld
of
bl
oo
d
ve
ss
el
**
**
*
(B) (C) (E)
(G)(F)
(D)
     |  2237LETTERS TO THE EDITOR
hyperplasia, whereas inflammatory cell infiltration and cytokine lev-
els were largely unaffected. This suggests that CPA activity is critical 
for AHR development and contributes to epithelial remodelling in this 
asthma model. It also suggests that CPA activity has a selective, local 
effect on airway smooth muscle and epithelium, compatible with the 
demonstrated accumulation of mast cells in these tissue compartments 
in asthma.1,4 Although inhibition of mast cell CPA3 is a likely explana-
tion for the dampening effect of NvCI in the asthma model, inhibition 
of other M14A carboxypeptidases cannot be excluded.7 To discriminate 
between the role of CPA3 and other carboxypeptidases, future studies 
including a battery of selective inhibitors of such enzymes and knockout 
mice are warranted. Our findings provide significant evidence for a det-
rimental role of carboxypeptidase in experimental asthma and highlight 
the biomedical potential of targeting carboxypeptidase activity in future 
asthma therapies.
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